Using patients as their own controls for cost evaluation of phase I clinical trials

Journal of Clinical Oncology

Volumn 22, Issue 7, 2004, Pages 1308-1314

  Sherman, Eric J ^a   Rubin, David M ^a   Venkatraman, Ennapadam ^a   Schwartz, Gary K ^a   Miller, Vincent A ^a   Radzyner, Mark H ^a   Ruchlin, Hirsch S ^a   Spriggs, David ^a   Pfister, David G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVOPIRIDOL; PACLITAXEL; PERILLYL ALCOHOL;

ARTICLE; CANCER PATIENT; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; HUMAN; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOLID TUMOR; ADULT; AGED; CANCER CENTER; COMPARATIVE STUDY; ECONOMICS; FEMALE; HEALTH CARE COST; HOSPITAL COST; MALE; MIDDLE AGED; NEOPLASM; PATIENT SELECTION; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; AGED; CANCER CARE FACILITIES; CLINICAL TRIALS, PHASE I; FEMALE; HEALTH CARE COSTS; HOSPITAL COSTS; HUMANS; MALE; MIDDLE AGED; MINNESOTA; NEOPLASMS; PATIENT SELECTION; PILOT PROJECTS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 2142718230     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.118     Document Type: Article

References (27)

1. Brown ML: The national economic burden of cancer. J Natl Cancer Inst 82:1811-1814, 1990
2. Wade JL, Weinberg PD, Bennett CL: Managed care's effects on community clinical research. Oncology News International, volume 8, 1999. http://www.cancernetwork.com/journals/ oncnews/n9905a.htm
3. Arnold K, Vastag B: Medicare to cover routine care costs in clinical trials. J Natl Cancer Inst 92:1032, 2000
4. Wagner JL, Alberts SR, Sloan JA, et al: Incremental costs of enrolling cancer patients in clinical trials: A population-based study. J Natl Cancer Inst 91:847-853, 1999
5. Fireman BH, Fehrenbacher L, Gruskin EP, et al: Cost of care for patients in cancer clinical trials. J Natl Cancer Inst 92:136-142, 2000
6. Bennett CL, Stinson TJ, Vogel V, et al: Evaluating the financial impact of clinical trials in oncology: Results from a pilot study from the Association of American Cancer Institutes/Northwestern University Clinical Trials Costs and Charges Project. J Clin Oncol 18:2805-2810, 2000
7. Smith TL, Lee JJ, Kantarjian HM, et al: Design and results of phase I cancer clinical trials: Three-year experience at M.D. Anderson Cancer Center. J Clin Oncol 14:287-295, 1996
8. Weiss NS, Heckbert SR: Patients as their own controls in studies of therapeutic efficacy. J Gen Intern Med 3:381-383, 1988
9. Harrison WM, Endicott J, Nee J: Treatment of premenstrual dysphoria with alprazolam: A controlled study. Arch Gen Psychiatry 47:270-275, 1990
10. Phillips BA, Schmitt FA, Berry DT, et al: Treatment of obstructive sleep apnea: A preliminary report comparing nasal CPAP to nasal oxygen in patients with mild OSA. Chest 98:325-330, 1990
11. Fauvel JP, Velon S, Berra N, et al: Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 28:259-263, 1996
12. Frederiksen SG, Johansson J, Johnsson F, et al: Neither low-calorie diet nor vertical banded gastroplasty influence gastro-oesophageal reflux in morbidly obese patients. Eur J Surg 166:296-300, 2000
13. Mahon J, Laupacis A, Donner A, et al: Randomised study of n of 1 trials versus standard practice. BMJ 312:1069-1074, 1996
14. Haines DR, Gaines SP: N of 1 randomised controlled trials of oral ketamine in patients with chronic pain. Pain 83:283-287, 1999
15. Jansen IH, Olde Rikkert MG, Hulsbos HA, et al: Toward individualized evidence-based medicine: Five "N of 1" trials of methylphenidate in geriatric patients. J Am Geriatr Soc 49:474-476, 2001
16. Hammond CM, Pierson JF, Grande TP, et al: Economic evaluation of risperidone in an outpatient population. Ann Pharmacother 33:1160-1166, 1999
17. Karnon J, Qizilbash N: Economic evaluation alongside n-of-1 trials: Getting closer to the margin. Health Econ 10:79-82, 2001
18. Azzoli CG, Miller VA, Ng KK, et al: A phase I trial of perillyl alcohol in patients with advanced solid tumors: Cancer Chemother Pharmacol 51:493-498, 2003
19. Schwartz GK, O'Reilly E, Ilson D, et al: Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 20:2157-2170, 2002
20. Finkler SA: The distinction between cost and charges. Ann Intern Med 96:102-109, 1982
21. Miller ME, Zuckerman S, Gates M: How do Medicare physician fees compare with private payers? Health Care Financ Rev 14:25-39, 1993
22. Sherman EJ, Pfister DG, Ruchlin HI, et al: The COIN form: A new tool to collect the invisible costs of hormone-refractory prostate cancer. Cancer 91:841-853, 2001
23. Wilcoxon F: Individual comparisons by ranking methods. Biometrics Bull 1:80, 1945
24. McCullagh P, Nelder J: Generalized Linear Models (ed 2). London, United Kingdom, Chapman and Hall, 1989
25. Eisenberg JM: Clinical economics: A guide to the economic analysis of clinical practices. JAMA 262:2879-2886, 1989
26. Marwick C: Insurers, employers ask for better evaluation of new technologies. JNCI 94:250-251, 2002
27. Goldman DP, Schoenbaum ML, Potosky AL, et al: Measuring the incremental cost of clinical cancer research. J Clin Oncol 19:105-110, 2001